Edition:
United Kingdom

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

0.52USD
18 Apr 2019
Change (% chg)

$-0.01 (-1.71%)
Prev Close
$0.53
Open
$0.52
Day's High
$0.54
Day's Low
$0.52
Volume
2,353,759
Avg. Vol
2,884,507
52-wk High
$2.58
52-wk Low
$0.49

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $338.31
Shares Outstanding(Mil.): 294.18
Dividend: --
Yield (%): --

Financials

  NVAX.OQ Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -0.77 -- --
ROI: -57.83 8.91 13.83
ROE: -829.23 10.06 15.25

Novavax shares plunge 65 percent as respiratory vaccine fails in late-stage trial

Novavax Inc shares crashed 65 percent on Thursday after data showed its vaccine failed to prevent RSV disease, a leading cause of respiratory infections in infants, missing the main goal of a late-stage study.

28 Feb 2019

UPDATE 1-Novavax respiratory infection vaccine fails in late-stage trial

Feb 28 Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.

28 Feb 2019

Novavax's respiratory infection vaccine fails in late-stage trial

Feb 28 Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.

28 Feb 2019

Earnings vs. Estimates